Search

Endometrial cancer is one of the most common malignancies of women, and in developed countries the most common of gyneco-oncological malignancies. Adequate treatment depends on the age of the patient, radiological stage of the disease, histological result of the primary biopsy at diagnosis. Postmenopausal or irregular bleeding is often an early alarming symptom of the disease; thus, it can lead to early diagnosis. Operative treatment should be performed based on the decision of a multidisciplinary tumor board with the results of final histology and operative staging postoperative tumor board can set up the adjuvant treatment plan if necessary. In advanced stage the most common therapeutic method is taxane and platinum-based chemotherapy but, molecular profile of the disease can open other immunotherapeutic opportunities, which can be continued as a maintenance therapy. In case of recurrent disease, the beside the option of chemotherapy immunotherapies could be applied as an individual therapy, after the results of its efficacy in progression-free and overall survival confirmed by multiple studies. In our article we are intending to summarize the recent advances in the treatment of the disease regarding the molecular classification and targeted treatment of endometrial cancer, having a robust impact not only on treatment strategies, but on the staging on the disease as well. [ABSTRACT FROM AUTHOR]

The article discusses updated data as of 2024 which shows that adjuvant pembrolizumab (Keytruda) extended overall survival (OS) in patients with clear cell renal cell carcinoma (ccRCC) at medium or high risk of recurrence. It states that the therapy improved disease-free survival (DFS) and lowered distant and local disease recurrence. Also noted are the occurrences of immune-mediated adverse events (AE) and infusion reactions among patients.

The article discusses results from an analysis of the phase three KEYNOTE-426 trial on the efficacy of a combination treatment with pembrolizumab and axitinib, compared with single agent sunitinib, in patients with clear cell renal cell carcinoma (CCRCC). The study evaluated overall survival, progression-free survival, overall response rate, complete response rate, partial response rare, stable disease rate in patients who received pembrolizumab/axitinib and those administered with sunitinib.